# RDD1609 as a Treatment for Idiopathic Pruritus Ani

> **NCT03757403** · PHASE2 · WITHDRAWN · sponsor: **RDD Pharma Ltd**

## Conditions studied

- Idiopathic Pruritus Ani

## Interventions

- **DRUG:** RDD1609
- **DRUG:** Mebendazole 100 MG

## Key facts

- **NCT ID:** NCT03757403
- **Lead sponsor:** RDD Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-01
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Covid-19
- **Last updated:** 2022-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757403, "RDD1609 as a Treatment for Idiopathic Pruritus Ani". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03757403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*